Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Inc EQ.OQ EQ.O is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Equillium Inc is for a loss of 5 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Equillium Inc is $7.00, about 231.8% above its last closing price of $2.11
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.04 | -0.04 | -0.06 | Missed | -38.5 |
Dec. 31 2026 | -0.06 | -0.06 | -0.04 | Beat | 33.3 |
Sep. 30 2025 | -0.07 | -0.14 | -0.06 | Beat | 58.6 |
Jun. 30 2025 | -0.23 | -0.18 | -0.16 | Beat | 13.5 |
Mar. 31 2025 | -0.34 | -0.33 | -0.24 | Beat | 28.4 |
Dec. 31 2024 | -0.31 | -0.16 | Beat | 48.4 | |
Sep. 30 2024 | -0.23 | -0.26 | 0.00 | Beat | 100 |
Jun. 30 2024 | -0.13 | -0.15 | 0.01 | Beat | 106.7 |
This summary was machine generated August 10 at 21:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations